Sociodemographic disparities in incidence rates of advanced and low-risk prostate cancer as a proxy for diagnostic activity
DOI:
https://doi.org/10.2340/1651-226X.2025.43399Keywords:
Prostate cancer, Early diagnosis, Socioeconomic factors, Ethnicity, Incidence studyAbstract
Background: Inequity in prostate cancer detection can be assessed by relating the diagnostic intensity to the incidence rate of advanced disease in different population groups, according to factors such as socioeconomic status or ethnicity.
Methods: We used nationwide Swedish register data from Prostate Cancer data Base Sweden 5.0 and Statistics Sweden, which enabled us to estimate incidence rates of low-risk prostate cancer (a proxy for diagnostic activity) and advanced disease (locally advanced and/or metastatic) across population groups according to household income, country of birth, and neighborhood-level characteristics.
Results: We found a gradient in the age-standardized incidence of low-risk prostate cancer across income groups, from 60 per 100,000/year in men with high to 34 per 100,000/year in men with low household income: adjusted incidence rate ratio (IRR) 0.65 (95% confidence interval [CI] 0.59–0.71). The gradient in the incidence of advanced disease had the opposite direction, from 44 to 60 per 100,000/year, IRR 1.43 (95% CI 1.31–1.56). Immigrants from a non-Nordic country (nearly 40% from Asia) had lower incidence rates of both low-risk (IRR 0.47, 95% CI 0.42–0.53) and advanced disease (IRR 0.65, 95% CI 0.58–0.73) than men born in a Nordic country. Neighborhood-level analysis considering economic standard, share of immigrants, and degree of urbanization did not clearly differentiate the incidence of advanced disease.
Interpretation: Our results suggest that measures to facilitate early detection of prostate cancer should be targeted to men with a low income. A low diagnostic activity for prostate cancer among immigrants from countries with low background risk may not imply unjustified social disparity.
Downloads
References
Clegg LX, Reichman ME, Miller BA, Hankey BF, Singh GK, Lin YD, et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control. 2009;20:417–35.
https://doi.org/10.1007/s10552-008-9256-0 DOI: https://doi.org/10.1007/s10552-008-9256-0
Houston KA, King J, Li J, Jemal A. Trends in prostate cancer incidence rates and prevalence of prostate specific antigen screening by socioeconomic status and regions in the United States, 2004 to 2013. J Urol. 2018;199:676–82.
https://doi.org/10.1016/j.juro.2017.09.103 DOI: https://doi.org/10.1016/j.juro.2017.09.103
Barclay ME, Abel GA, Greenberg DC, Rous B, Lyratzopoulos G. Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact. Br J Cancer. 2021;124:1320–9.
https://doi.org/10.1038/s41416-021-01279-z DOI: https://doi.org/10.1038/s41416-021-01279-z
Khadhra HB, Saint F, Trecherel E, Lapotre-Ledoux B, Zerkly S, Ganry O. Relationship between socioeconomic status and prostate cancer (incidence, aggressiveness, treatment with curative intent, and mortality): a spatial analysis using population-based cancer registry data. Rev Epidemiol Sante Publique. 2021;69:329–36.
https://doi.org/10.1016/j.respe.2021.07.007 DOI: https://doi.org/10.1016/j.respe.2021.07.007
Dodkins J, Cook A, Mayne E, Parry M, Nossiter J, Payne H, et al. Geographic, socioeconomic and demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England: a population-based evaluation. BMJ Oncol. 2025;4:e000643.
https://doi.org/10.1136/bmjonc-2024-000643 DOI: https://doi.org/10.1136/bmjonc-2024-000643
Ammitzboll G, Levinsen AKG, Kjaer TK, Ebbestad FE, Horsbol TA, Saltbaek L, et al. Socioeconomic inequality in cancer in the Nordic countries. A systematic review. Acta Oncol. 2022;61:1317–31.
https://doi.org/10.1080/0284186X.2022.2143278 DOI: https://doi.org/10.1080/0284186X.2022.2143278
Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer – results from a prospective, population-based randomized controlled trial. Eur Urol. 2007;51:659–64.
https://doi.org/10.1016/j.eururo.2006.07.012 DOI: https://doi.org/10.1016/j.eururo.2006.07.012
Hugosson J, Roobol MJ, Månsson M, Tammela TLJ, Zappa M, Nelen V, et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur Urol. 2019;76:43–51.
https://doi.org/10.1016/j.eururo.2019.02.009 DOI: https://doi.org/10.1016/j.eururo.2019.02.009
Bratt O, Auvinen A, Arnsrud Godtman R, Hellström M, Hugosson J, Lilja H, et al. Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps. BMJ Oncol. 2023;2(e000039):1–13.
https://doi.org/10.1136/bmjonc-2023-000039 DOI: https://doi.org/10.1136/bmjonc-2023-000039
Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Goteborg randomized population-based prostate cancer screening trial. Eur Urol. 2015;68:354–60.
https://doi.org/10.1016/j.eururo.2014.12.006 DOI: https://doi.org/10.1016/j.eururo.2014.12.006
Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 update on prostate cancer epidemiology and risk factors – a systematic review. Eur Urol. 2023;84:191–206.
https://doi.org/10.1016/j.eururo.2023.04.021 DOI: https://doi.org/10.1016/j.eururo.2023.04.021
Goddard KAB, Feuer EJ, Umar A, Castle PE. Accelerating progress to reduce the cancer burden through prevention and control in the United States. J Natl Cancer Inst. 2025;117:20–8.
https://doi.org/10.1093/jnci/djae204 DOI: https://doi.org/10.1093/jnci/djae204
Stranne J. 2023/2024 update of the national prostate cancer guidelines in Sweden. Scand J Urol. 2024;59:210–1. https.//doi.org/10.2340/sju.v59.42656 DOI: https://doi.org/10.2340/sju.v59.42656
Stattin P. How to improve cancer care by use of guidelines and quality registers. Scand J Urol. 2024;59:190–2.
https://doi.org/10.2340/sju.v59.42272 DOI: https://doi.org/10.2340/sju.v59.42272
Tomic K, Berglund A, Robinson D, Hjälm-Eriksson M, Carlsson S, Lambe M, et al. Capture rate and representativity of The National Prostate Cancer Register of Sweden. Acta Oncol. 2015;54:158–63.
https://doi.org/10.3109/0284186X.2014.939299 DOI: https://doi.org/10.3109/0284186X.2014.939299
Van Hemelrijck M, Garmo H, Wigertz A, Nilsson P, Stattin P. Cohort profile update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base – a refined prostate cancer trajectory. Int J Epidemiol. 2016;45:73–82.
https://doi.org/10.1093/ije/dyv305 DOI: https://doi.org/10.1093/ije/dyv305
Statistics Sweden. Att mäta segregation på låg regional nivå. Reference no. 2017/1421 [Report in Swedish]. [cited 2028 Mar 18]. Available from: https://www.scb.se/contentassets/deedfb3fbe3d4abd987cfcd67dcff2e4/slutrapport-att-mata-segregation-pa-lag-regional-niva._ku2017_02404_d.pdf
Strömberg U, Baigi A, Holmén A, Parkes BL, Bonander C, Piel FB. A comparison of small-area deprivation indicators for public-health surveillance in Sweden. Scand J Public Health. 2023;51:520–6.
https://doi.org/10.1177/14034948211030353 DOI: https://doi.org/10.1177/14034948211030353
Allik M, Leyland A, Travassos Ichihara MY, Dundas R. Creating small-area deprivation indices: a guide for stages and options. Epidemiol Community Health. 2020;74:20–5.
https://doi.org/10.1136/jech-2019-213255 DOI: https://doi.org/10.1136/jech-2019-213255
Breslow NE, Day NE. Statistical methods in cancer research, volume II: the design and analysis of cohort studies. Lyon: International Agency for Research on Cancer, World Health Organisation; 1987.
Blangiardo M, Cameletti M. Spatial and Spatio-temporal Bayesian models with R-INLA. New York, NY: Wiley; 2015. DOI: https://doi.org/10.1002/9781118950203
Berglund A, Garmo H, Robinson D, Tishelman C, Holmberg L, Bratt O, et al. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer. Eur J Cancer. 2012;48:75–84.
https://doi.org/10.1016/j.ejca.2011.07.009 DOI: https://doi.org/10.1016/j.ejca.2011.07.009
Li X, Sundquist K, Sundquist J. Neighborhood deprivation and prostate cancer mortality: a multilevel analysis from Sweden. Prostate Cancer Prostatic Dis. 2012;15:128–34.
https://doi.org/10.1038/pcan.2011.46 DOI: https://doi.org/10.1038/pcan.2011.46
Tomic K, Ventimiglia E, Robinson D, Häggström C, Lambe M, Stattin P. Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study. Int J Cancer. 2018;142:2478–84.
https://doi.org/10.1002/ijc.31272 DOI: https://doi.org/10.1002/ijc.31272
Järbur E, Holmberg E, Björk-Eriksson T, Bratt O, Arnsrud Godtman R. Associations between socioeconomic factors and PSA testing in a population-based organised testing programme and routine healthcare: a register-based study of 50-year-old men. BMJ Oncol. 2024;3:1–7.
https://doi.org/10.1136/bmjonc-2024-000400 DOI: https://doi.org/10.1136/bmjonc-2024-000400
Hugosson J, Godtman RA, Carlsson SV, Aus G, Grenabo Bergdahl A, Lodding P, et al. Eighteen-year follow-up of the Goteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scand J Urol. 2018;52:27–37.
https://doi.org/10.1080/21681805.2017.1411392 DOI: https://doi.org/10.1080/21681805.2017.1411392
Strömberg U, Berglund A, Carlsson S, Thellenberg Karlsson C, Lambe M, et al. Socioeconomic inequality in prostate cancer diagnostics, primary treatment, rehabilitation, and mortality in Sweden. Int J Cancer. 2024;155:637–45.
https://doi.org/10.1002/ijc.34932 DOI: https://doi.org/10.1002/ijc.34932
Loeb S, Drevin L, Robinson D, Holmberg E, Carlsson S, Lambe M, et al. Risk of localized and advanced prostate cancer among immigrants versus native-born Swedish men: a nation-wide population-based study. Cancer Causes Control. 2013;24:383–90.
https://doi.org/10.1007/s10552-012-0124-6 DOI: https://doi.org/10.1007/s10552-012-0124-6
Diez-Roux AV, Mair C. Neighborhoods and health. Ann N Y Acad Sci. 2010;1186:125–45.
https://doi.org/10.1111/j.1749-6632.2009.05333.x DOI: https://doi.org/10.1111/j.1749-6632.2009.05333.x
Strömberg U. How can precision prevention be approached from a general population perspective within the field of cancer epidemiology? Acta Oncol. 2021;60:1272–4.
https://doi.org/10.1080/0284186X.2021.1962544 DOI: https://doi.org/10.1080/0284186X.2021.1962544
Seikkula H, Kaipia A, Boström PJ, Malila N, Pitkäniemi J, Seppä K. Periodic trends in geographical variation of prostate cancer incidence and mortality in Finland between 1985 and 2019. Acta Oncol. 2022;61:1209–15.
https://doi.org/10.1080/0284186X.2022.2112971 DOI: https://doi.org/10.1080/0284186X.2022.2112971
Nugin H, Folkvaljon Y, Damber JE, Adolfsson J, Robinson D, Stattin P. Work-up and treatment of prostate cancer before and after publication of the first national guidelines on prostate cancer care in Sweden. Scand J Urol. 2018;52:277–84.
https://doi.org/10.1080/21681805.2018.1512650 DOI: https://doi.org/10.1080/21681805.2018.1512650
Strömberg U, Parkes BL, Holmén A, Peterson S, Holmberg E, Baigi A, et al. Disease mapping of early- and late-stage cancer to monitor inequalities in early detection: a study of cutaneous malignant melanoma. Eur J Epidemiol. 2020;35:537–47.
https://doi.org/10.1007/s10654-020-00637-0 DOI: https://doi.org/10.1007/s10654-020-00637-0
Additional Files
Published
How to Cite
License
Copyright (c) 2025 Ulf Strömberg, Carl Bonander, Hans Garmo, Mats Lambe, Pär Stattin, Ola Bratt
This work is licensed under a Creative Commons Attribution 4.0 International License.
